CRISPR Therapeutics AG [NASDAQ: CRSP] closed the trading session at $80.70 on 07/13/22. The day’s price range saw the stock hit a low of $75.0438, while the highest price level was $82.68. The company report on June 11, 2022 that CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical benefit for 90% of patients-.
-Well tolerated safety profile across all dose levels with no DLTs observed-.
The stocks have a year to date performance of 6.49 percent and weekly performance of 11.00 percent. The stock has been moved at 16.80 percent over the last six months. The stock has performed 26.57 percent around the most recent 30 days and changed 31.33 percent over the most recent 3-months.
If compared to the average trading volume of 1.92M shares, CRSP reached to a volume of 3251765 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about CRISPR Therapeutics AG [CRSP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRSP shares is $114.48 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRSP stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for CRISPR Therapeutics AG shares, keeping their opinion on the stock as In-line, with their previous recommendation back on June 23, 2022. While these analysts kept the previous recommendation, BMO Capital Markets raised their target price to Outperform. The new note on the price target was released on June 17, 2022, representing the official price target for CRISPR Therapeutics AG stock. Previously, the target price had yet another raise to $78, while Credit Suisse analysts kept a Neutral rating on CRSP stock.
The Average True Range (ATR) for CRISPR Therapeutics AG is set at 6.18, with the Price to Sales ratio for CRSP stock in the period of the last 12 months amounting to 6.96. The Price to Book ratio for the last quarter was 2.77, with the Price to Cash per share for the same quarter was set at 28.13. Price to Free Cash Flow for CRSP in the course of the last twelve months was 15.38 with Quick ratio for the last quarter at 19.90.
CRSP stock trade performance evaluation
CRISPR Therapeutics AG [CRSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.00. With this latest performance, CRSP shares gained by 26.57% in over the last four-week period, additionally plugging by 16.80% over the last 6 months – not to mention a drop of -40.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRSP stock in for the last two-week period is set at 65.13, with the RSI for the last a single of trading hit 68.95, and the three-weeks RSI is set at 62.47 for CRISPR Therapeutics AG [CRSP]. The present Moving Average for the last 50 days of trading for this stock 60.83, while it was recorded at 77.67 for the last single week of trading, and 70.88 for the last 200 days.
CRISPR Therapeutics AG [CRSP]: An insightful look at the core fundamentals
CRISPR Therapeutics AG’s liquidity data is similarly interesting compelling, with a Quick Ratio of 19.90 and a Current Ratio set at 19.90.
CRISPR Therapeutics AG [CRSP]: Insider Ownership positions
There are presently around $4,082 million, or 61.50% of CRSP stock, in the hands of institutional investors. The top three institutional holders of CRSP stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 9,727,531, which is approximately 3.44% of the company’s market cap and around 0.50% of the total institutional ownership; NIKKO ASSET MANAGEMENT AMERICAS, INC., holding 4,619,747 shares of the stock with an approximate value of $365.19 million in CRSP stocks shares; and SUMITOMO MITSUI TRUST HOLDINGS, INC., currently with $365.19 million in CRSP stock with ownership of nearly New of the company’s market capitalization.
Positions in CRISPR Therapeutics AG stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 240 institutional holders increased their position in CRISPR Therapeutics AG [NASDAQ:CRSP] by around 13,497,952 shares. Additionally, 165 investors decreased positions by around 4,940,744 shares, while 106 investors held positions by with 33,204,628 shares. The mentioned changes placed institutional holdings at 51,643,324 shares, according to the latest SEC report filing. CRSP stock had 68 new institutional investments in for a total of 6,086,776 shares, while 69 institutional investors sold positions of 3,128,412 shares during the same period.